U.S. Entertainment Stock News

NYSE:USFD
NYSE:USFDConsumer Retailing

Is US Foods (USFD) Using Buybacks And Tuck-In Deals To Quietly Redraw Its Growth Map?

In early May 2026, US Foods Holding Corp. reported modest year-on-year first-quarter growth in sales and earnings, completed a US$983.6 million buyback program, and reaffirmed its 2026 net sales growth outlook of 4% to 6% despite weather and fuel headwinds. The company also highlighted continued market share gains and an active capital deployment agenda, including further share repurchases and tuck-in acquisitions funded by ongoing cash generation. Against this backdrop, we'll examine how...
NYSE:RCL
NYSE:RCLHospitality

A Look At Royal Caribbean Cruises (RCL) Valuation After Strong Q1 2026 Results And 10% Revenue Growth Guidance

First quarter earnings and guidance catch investor attention Royal Caribbean Cruises (RCL) has drawn fresh interest after reporting first quarter 2026 results with higher revenue and net income versus a year earlier, alongside full year guidance pointing to roughly 10% revenue growth. See our latest analysis for Royal Caribbean Cruises. RCL shares closed at US$264.20 and, despite a 2.36% 1 day share price gain after the earnings and guidance update plus the announced US$1.50 quarterly...
NYSE:A
NYSE:ALife Sciences

Agilent Technologies (A) Valuation Check As New Biopharma Collaborations And Logic Analyzers Expand Growth Story

Agilent Technologies (A) has been active on several fronts recently, from new collaborations in biopharma analytics to the launch of its 16850 Series portable logic analyzers, giving investors fresh context for assessing the stock. See our latest analysis for Agilent Technologies. Despite fresh product launches and new biopharma collaborations shaping sentiment, Agilent’s share price has eased recently. The 30-day share price return is down 4.05% and the year-to-date share price return is...
NasdaqGS:ADTN
NasdaqGS:ADTNCommunications

ADTRAN’s Narrower Loss and CTO Stock Moves Might Change The Case For Investing In ADTN

In the first quarter of 2026, ADTRAN Holdings, Inc. reported revenue of US$286.09 million and a net loss of US$1.32 million, alongside issuing second-quarter revenue guidance of US$283.0 million to US$303.0 million and disclosing recent stock option exercises and share sales by its Chief Technology Officer. The combination of year-over-year revenue growth, a sharply smaller net loss, and quantified near-term revenue expectations gives investors clearer insight into ADTRAN’s operating...
NasdaqGS:AUGO
NasdaqGS:AUGOMetals and Mining

Aura Minerals (AUGO) Is Down 11.6% After Record Q1 Profit And New Mine Buildout News

Aura Minerals Inc. has already reported first-quarter 2026 results, with sales rising to US$382.61 million and net income reaching US$95.16 million, alongside record gold-equivalent production of 82,100 ounces driven by the MSG acquisition and Borborema’s ramp-up. The company also began construction of its Era Dorada project after securing permits and board approval, adding another growth option to a portfolio where management is reaffirming 2026 production guidance while highlighting...
NYSE:RL
NYSE:RLLuxury

Ralph Lauren’s USPS Stamp Role Puts Brand Power In Fresh Focus

Ralph Lauren is curating the USPS American Icons stamp collection, the first time an individual designer has overseen a full official USPS series. The collaboration coincides with preparations for America's 250th anniversary and includes a commemorative capsule collection in Ralph Lauren stores and online. The project links the NYSE:RL brand directly to a high profile national cultural celebration beyond traditional fashion partnerships. For investors tracking NYSE:RL, this project arrives...
NYSE:VPG
NYSE:VPGElectronic

Why Vishay Precision Group (VPG) Is Up 56.7% After Strong Q1 Beat And Robust Q2 Outlook

In the first quarter of fiscal 2026, Vishay Precision Group reported net revenues of US$84.35 million, a smaller net loss of US$0.319 million compared with a year earlier, and issued second‑quarter revenue guidance of US$85 million to US$90 million, all of which surpassed analyst expectations and reflected broad-based demand across its core segments. Orders exceeded US$100 million, lifting the book-to-bill ratio to 1.21 and backlog to about US$125 million, highlighting strong order...
NasdaqGS:DFTX
NasdaqGS:DFTXPharmaceuticals

Definium Therapeutics (DFTX) Is Down 6.0% After Starting Second Phase 3 DT120 Trial in MDD - Has The Bull Case Changed?

In May 2026, Definium Therapeutics dosed the first patient in Ascend, its second Phase 3 trial of DT120 ODT for major depressive disorder, a 175‑patient U.S. study assessing changes in Montgomery-Åsberg Depression Rating Scale scores over 12 weeks versus placebo. This milestone extends Definium’s late-stage program for its proprietary fast-dissolve lysergide tablet, aiming to show antidepressant effects while addressing concerns about functional unblinding through a three-arm dosing...
NYSE:LH
NYSE:LHHealthcare

Evaluating Labcorp Holdings (LH) After Expanded Epic Partnership And An 18% Estimated Valuation Gap

Labcorp Holdings (LH) is back in focus after announcing an expanded collaboration with Epic, embedding its full diagnostic test menu into Epic's Aura platform to simplify ordering and results for hospitals and health systems. See our latest analysis for Labcorp Holdings. Recent share price performance has been softer, with the stock down 8.52% on a 3 month share price basis and 3.69% over 1 month. However, the 1 year total shareholder return of 6.10% and 3 year total shareholder return of...
NYSE:SO
NYSE:SOElectric Utilities

How Investors Are Reacting To Southern (SO) Massive DOE Loan And Customer Bill-Relief Moves

The Southern Company recently reported past first-quarter 2026 results, with revenue of US$8,397 million and net income of US$1,356 million, and highlighted a US$26.50 billion Department of Energy loan alongside customer savings from Georgia regulatory agreements. Together, these earnings, financing, and bill-reduction developments underscore how Southern is pairing large-scale infrastructure investment with efforts to limit long-term cost pressure for customers. Next, we’ll examine how this...
NYSE:TEVA
NYSE:TEVAPharmaceuticals

How Investors May Respond To Teva (TEVA) Showcasing CNS Growth And Emalex Deal At Key Conferences

In May 2026, Teva Pharmaceutical Industries Limited presented at the Bank of America Global Healthcare Conference in Las Vegas and at BioMed Israel in Tel Aviv, highlighting its central nervous system portfolio and research progress through senior executives Eric A. Hughes and Eran Harary. These appearances came shortly after Teva reported that sales from its central nervous system medicines, including Ajovy, Uzedy, and Austedo, rose very large year-on-year to US$837 million in the first...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Intuit’s Vapi Partnership Puts Voice AI At Core Of Product Story

Vapi closed a US$50 million Series B round, naming Intuit (NasdaqGS:INTU) as a key enterprise customer for its voice AI platform. The funding highlights Intuit’s role as a flagship user of advanced voice AI tools aimed at customer interaction and support. This development adds a new external AI partnership to Intuit’s broader push to embed AI across its product ecosystem. For you as an investor, this ties directly into how Intuit is positioning its core franchises in tax, small business...
NasdaqGS:ALKS
NasdaqGS:ALKSBiotechs

Why Alkermes (ALKS) Is Up 10.2% After Positive Phase 3 LUMRYZ Idiopathic Hypersomnia Data

On May 12, 2026, Alkermes announced positive topline Phase 3 REVITALYZ results showing that once‑nightly LUMRYZ improved excessive daytime sleepiness and other idiopathic hypersomnia symptoms versus placebo, supporting plans to file a supplemental New Drug Application with the FDA by the end of 2026. A key nuance for investors is that, under an existing settlement, Alkermes cannot market LUMRYZ for idiopathic hypersomnia before March 1, 2028, even if it secures earlier FDA approval. We’ll...
NasdaqGS:GILD
NasdaqGS:GILDBiotechs

Gilead Liver Data At EASL Tests Case For A Third Growth Pillar

Gilead Sciences (NasdaqGS:GILD) plans to present new liver disease data at the upcoming EASL Congress. The company will showcase pivotal Phase 3 results for Livdelzi (seladelpar) in primary biliary cholangitis. Additional updates will cover progress on investigational hepatitis delta virus treatments, including bulevirtide. Gilead Sciences is putting more attention on its liver disease pipeline, which sits alongside its well known HIV and oncology franchises. The stock trades at $133.05,...
NasdaqGS:FOXA
NasdaqGS:FOXAMedia

A Look At Fox (FOXA) Valuation As Q3 Earnings Beat And Tubi Growth Support Investor Optimism

Why Fox (FOXA) stock is back in focus after earnings and buybacks Fox (FOXA) is back on investors’ radar after a solid earnings surprise and an update on its long running share repurchase program, combining operating resilience with sizeable capital returns. See our latest analysis for Fox. Fox’s earnings beat, renewed buyback activity and upcoming conference appearance have arrived alongside a 17.79% 90 day share price return, while the stock’s 1 year total shareholder return of 22.81% sits...
NasdaqGM:LMAT
NasdaqGM:LMATMedical Equipment

Why LeMaitre Vascular (LMAT) Is Down 10.9% After Raising 2026 Guidance And Boosting Dividends

Earlier in May 2026, LeMaitre Vascular, Inc. reported first-quarter sales of US$66.55 million and net income of US$15.68 million, raised its full-year 2026 sales and earnings guidance, and its board approved a US$0.25 quarterly dividend payable on June 4, 2026. These stronger results and upgraded outlook, alongside upcoming investor outreach at the Bank of America Global Healthcare Conference, highlight management’s confidence in the company’s operating trajectory and cash-generating...
NasdaqCM:ONDS
NasdaqCM:ONDSCommunications

Should Ondas’ (ONDS) Mistral Defense Merger and New Demining Contracts Require Action From Investors?

Ondas Inc. has already reported that it will release its Q1 2026 results and host an earnings call on May 14, 2026, alongside completing a US$175.00 million merger with defense prime contractor Mistral Inc. that expands its access to U.S. military contract channels and domestic manufacturing capabilities. Recent contract wins, including a US$10.00 million initial demining order for Israel’s Eastern Border Security Barrier via subsidiary 4M Defense, underscore how Ondas is repositioning...
NasdaqGS:SEIC
NasdaqGS:SEICCapital Markets

SEI Investments Carlyle Partnership Highlights Private Markets Push And Valuation Gap

SEI Investments (NasdaqGS:SEIC) and Carlyle have expanded their partnership to broaden private markets access for wealth and retirement investors. The collaboration focuses on developing new private market solutions and joint offerings for wealth management and retirement channels. The move reflects a material change in SEI Investments' approach to private markets within its product lineup. SEI Investments operates across investment processing, investment management, and investment...
NasdaqGS:ASML
NasdaqGS:ASMLSemiconductor

Assessing ASML Holding’s (NasdaqGS:ASML) Valuation After Its Strong Recent Share Price Momentum

Why ASML Holding (NasdaqGS:ASML) is back on investors’ radar ASML Holding (NasdaqGS:ASML) is drawing fresh attention after its recent share price move, with the stock up 3.99% over the past day and 5.42% over the past month. Those short term gains sit alongside a 12.42% rise over the past 3 months and a 35.90% year to date return. This has prompted investors to reassess how the company’s earnings profile and valuation connect to long term expectations. See our latest analysis for ASML...
NYSE:WAT
NYSE:WATLife Sciences

Is It Time To Reassess Waters (WAT) After A Choppy Share Price Performance?

If you are wondering whether Waters at around US$334.93 is offering good value or if the market is pricing in too much optimism, this article breaks down what the current share price may be implying. The stock has been choppy, with the price falling 4.2% over the last week, rising 3.2% over the last month, and still sitting down 12.3% year to date and down 3.0% over the past year, alongside a 26.9% gain over three years and 9.3% over five years. Recent coverage has focused on how these mixed...
NYSE:CLH
NYSE:CLHCommercial Services

Assessing Clean Harbors (CLH) Valuation After Recent Share Price Strength And PFAS Growth Story

Why Clean Harbors stock is drawing fresh attention Clean Harbors (CLH) is back on investors’ radar after a strong past 3 months, with the stock up about 13.5% and trading near its recent close of US$302.95. That move sits alongside full year revenue of US$6.06b and net income of US$395.50m, giving investors concrete figures to weigh against the company’s current valuation and recent share price momentum. See our latest analysis for Clean Harbors. Beyond the recent 3 month move, the stock’s 1...
NYSE:ZIM
NYSE:ZIMShipping

ZIM Takeover Battle With Hapag-Lloyd And Sakal Tests Valuation Case

ZIM Integrated Shipping Services is at the center of a takeover contest, with competing interest from Hapag-Lloyd and Sakal Group. ZIM's board has reaffirmed support for its binding merger agreement with Hapag-Lloyd, despite a higher offer from Sakal Group. Hapag-Lloyd has made commitments regarding Israeli operations and staff as part of its proposed merger with ZIM. For investors watching NYSE:ZIM, the merger contest arrives after a period of strong multi year share performance, with the...
NYSE:LEN
NYSE:LENConsumer Durables

Assessing Lennar (LEN) Valuation After A Steep Three Month Share Price Pullback

Recent performance snapshot Lennar (LEN) has been under pressure recently, with the stock down about 1% over the past day, 6% over the past week, and roughly 5% over the past month. The decline is steeper over the past 3 months, with the share price down about 30%, contributing to a year to date fall of around 18% and a 1 year total return decline of about 20%. See our latest analysis for Lennar. With the share price at $84.97, Lennar’s recent weakness, including a 90 day share price return...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

CrowdStrike Award Highlights Identity Security Strength As Valuation Raises Questions

CrowdStrike Holdings (NasdaqGS:CRWD) was named Frost & Sullivan's 2026 Company of the Year for Identity Threat Detection and Response. The award highlights the company's focus on protecting human, machine, and AI agent identities. Frost & Sullivan cited advances in AI and continuous authorization as key factors in the recognition. For investors tracking cybersecurity, this award adds a fresh data point on where CrowdStrike, through its NasdaqGS:CRWD stock, is positioned in identity...